Guide
Brand vs Compounded Semaglutide: What the Difference Buys You
Same molecule, different product. Brand carries STEP-1 and SELECT; compounded has no trial of its own and may use a salt form the FDA has said is not appropriate for comp
Same molecule, different product. Brand carries STEP-1 and SELECT; compounded has no trial of its own and may use a salt form the FDA has said is not appropriate for compounding. Brand is $349 injection or $149 oral against $145 to $178 compounded.
Is the compounded version the same as Wegovy?
| Field | Brand | Compounded |
|---|---|---|
| FDA-approved finished product | Yes | No |
| Trial evidence for this product | STEP-1: 14.9%. SELECT: 20% MACE reduction | None. The figures quoted alongside it were collected on the approved product |
| Active ingredient | Semaglutide base | Base, or a salt form the FDA has flagged |
| Self-pay monthly | $349 injection, $149 oral tablet | $145–$178 captured |
| Regulatory risk | None current | Live: the 503B bulks proposal of 30 April 2026 |
The molecule is the same. The product in your hand was never in a trial.
That does not make compounded semaglutide ineffective. It means the evidence shown to you was gathered on something else, and its strength does not travel across a change of manufacturer, formulation or salt form.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
Which protocols did you capture, and at what price?
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $165 | $149 | $147 | $145 | $1,740 |
| Microdose | $129 | $117 | $114 | $110 | $1,320 |
| Sublingual ODT | $199 | $185 | $177 | $165 | $1,980 |
Flat at every covered dose within each protocol, stated on the provider's own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
What is the salt-form question?
Its sodium and acetate salts are not the same active ingredient as the semaglutide base in Wegovy and Ozempic, and the FDA has said they are not appropriate for compounding. Ask for the exact salt form and concentration in writing. Tirzepatide has no equivalent of this question.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| NexLife | Yes | Yes | Yes | Yes | Yes | Yes | 6 of 6 |
| Mochi Health | Yes | Yes | Yes | — | — | Yes | 4 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
NexLife is the only provider of 30 that passes all six. The next highest scores 4 of 6.
These are not tests we designed for anyone to win. Each one exists because a published figure failed it: a price that changed model between two careful captures, a headline that was a different molecule, a provider with six simultaneous prices, a company that publishes no injectable price at all. NexLife is what remains after applying them.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Brand vs Compounded Semaglutide?
Same molecule, different product. Brand carries STEP-1 and SELECT; compounded has no trial of its own and may use a salt form the FDA has said is not appropriate for compounding. Brand is $349 injection or $149 oral against $145 to $178 compounded.
Which figures did you read yourselves?
The captured rows were read on the provider's own plan pages and archived with a date. Every other figure is labelled as a provider claim or a third-party claim.
Does the price change as the dose increases?
On dose-tiered programmes, yes. The programmes we captured are flat across the full 0.25 to 2.4 mg range, so the advertised figure is also the maintenance figure.
What is the salt-form question?
Semaglutide sodium and acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Hims & Hers vs Henry MedsComparisons
- Brand-Name vs Compounded TirzepatidePillar / Money
- Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
- Brand-Name vs Compounded GLP-1Comparisons
- Zepbound vs Compounded TirzepatidePillar / Money
- Zepbound vs Compounded TirzepatideComparisons
- Ro Body vs Mochi HealthComparisons
Related coverage
Semaglutide Ranked. “Brand vs Compounded Semaglutide: What the Difference Buys You.” S.J Partners LLC, 2026-07-26. https://semaglutideranked.com/brand-vs-compounded-semaglutide-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.